Business
Investor presentation
Investor presentation.
About this update from Diaceutics Plc
[{"type":"text","content":"\n \nRNS Number : 2012A Diaceutics PLC 28 May 2019 \n\n \nDiaceutics PLC\n(\"Diaceutics\" or the \"Company\")\n \nInvestor presentation\n \nDiaceutics PLC (AIM: DXRX), the data analytics and implementation services company which services the global pharmaceutical industry, announces it will hold an investor presentation on Monday, 17 June 2019.\n \nThe investor event will take place at the Copper Bar, Balls Brothers, 6 Adams Court, London EC2N 1DX at 4.30pm for a 4.45pm start. This will be followed by drinks and canapés, and a chance to network with the management. \n \nPeter Keeling, CEO, will provide an introduction to the Company and an overview of the business. \n \nIf you would like to register to attend the investor briefing or require further information, please contact Walbrook PR on 020 7933 8780 or email [email protected].\nNo new material information will be disclosed at the event.\nEnquiries:\n \n\n\n\nDiaceutics PLC\n\n\nwww.diaceutics.com \n\n\n\n\nPeter Keeling, Chief Executive Officer\n\n\nVia Walbrook PR\n\n\n\n\nPhilip White, Chief Financial Officer\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nWalbrook PR\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nAnna Dunphy\n\n\nMob: +44 (0)7876 741 001\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\n\n\n\n\n \n \nAbout Diaceutics\nDiaceutics has established a suite of data-driven products and implementation services powered by the data held in its proprietary database. Its products and services are focused on optimising its clients' strategies for the development and launch of precision medicines and specifically, the diagnostic testing required to guide selection of such medicines. The Company provides services to 20 of the 30 largest global pharmaceutical companies. \n \nSince its inception in 2005, Diaceutics has focused on the diagnostic testing market, collating large amounts of laboratory, patient (on an anonymised and aggregated basis), claims and payor data which it uses to deliver diagnostic testing strategies to its clients. The Group has amassed a set of more than 115 million patient records from over 2,500 laboratories across 35 countries around the world. As part of this data collection, it has accumulated a proprietary database of laboratory capabilities across the...